Sökning: "unga cancer"

Visar resultat 1 - 5 av 20 avhandlingar innehållade orden unga cancer.

  1. 1. Tumors associated with Hereditary Nonpolyposis Colorectal Cancer: Defective Mismatch Repair and Familial Risk of Cancer

    Författare :Kajsa Ericson Lindquist; Bröstcancer-genetik; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; oncology; cancerology; Cytologi; onkologi; cancer; Multiple Tumors; Hereditary Nonpolyposis Colorectal Cancer; Cytology; Cohort study; Population based; Familial Risk of Cancer; Immunohistochemistry; MSH2; MSH6; MLH1; Microsatellite Instability; Soft Tissue Sarcomas; Cancer of the Upper Urinary Tract; Cancer of the Small Intestine; Colorectal Cancer;

    Sammanfattning : Inactivation of the DNA mismatch repair (MMR) system is a tumorigenic mechanism involved in 15-20% of tumor types such as colorectal and endometrial cancer and is specifically associated with the Hereditary Nonpolyposis Colorectal Cancer (HNPCC) syndrome. These MMR defective tumors are characterized by microsatellite instability (MSI), a phenomenon that reflects alterations in length of repeated sequences, and 90% of MSI tumors show loss of immunohistochemical expression for the MMR protein affected. LÄS MER

  3. 2. Clinical Aspects of Hereditary Breast Cancer

    Författare :Niklas Loman; Bröstcancer-genetik; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; cancer; Cytologi; onkologi; cancerology; oncology; Cytology; Age of onset; Survival analysis; Incidence; Male breast cancer; Steroid receptors; BRCA2; BRCA1; Breast cancer; hereditary;

    Sammanfattning : A positive family history of breast cancer (BC) is one of the strongest predictors of the disease. Two major BC susceptibility genes, BRCA1 and BRCA2 were identified about a decade ago. In this thesis, studies of different biological. clinical and epidemiological aspects of hereditary BC are presented. LÄS MER

  4. 3. Rectal Cancer - Tumor Biology and Prognostic Markers

    Författare :Eva Fernebro; Bröstcancer-genetik; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; prognostic markers; Cytology; oncology; cancerology; Cytologi; onkologi; cancer; immunohistochemistry IHC ; chromosomal instability CIN ; microsatellite instability MSI ; tissue microarray TMA ; tissue inhibitor of metalloproteinase 1 TIMP-1 ; Rectal cancer; soluble urokinase plasminogen activator receptor suPAR ;

    Sammanfattning : Colorectal cancer is one of our most common malignancies and the second leading cause of cancer death worldwide. About 1/3 of the tumors are located in the rectum. LÄS MER

  5. 4. Predicting Prognosis and Tamoxifen Response in Breast Cancer. With a special focus on contralateral breast cancer

    Författare :Sara Alkner; Bröstcancer-genetik; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Breast cancer; prognosis; treatment prediction; endocrine treatment; tamoxifen; coactivator; AIB1; PAX2; SRC; contralateral breast cancer; premenopausal; randomized trial; mode of detection; mammography.;

    Sammanfattning : One of the great challenges in breast cancer treatment today is to customize adjuvant treatment to each patient’s individual needs. To do this it is necessary to learn more about the prognostic and treatment predictive factors that determine the risk of relapse and response to a certain mode of treatment. LÄS MER

  7. 5. Impact of Lifestyle, Hormones, and Genes on Breast Cancer

    Författare :Maria Hietala; Bröstcancer-genetik; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Breast cancer; BRCA1; BRCA2; androgen receptor; CAG; GGC; polymorphism; htSNP; oral contraceptives; testosterone; breast-feeding; prolactin; premenopausal women; CYP2D; complementary and alternative medicin; antidepressants;

    Sammanfattning : Approximately 7000 women are diagnosed and 1500 women die from breast cancer in Sweden every year. The aim of this thesis was to study the interplay of polymorphisms, hormone levels, lifestyle, and the use of concomitant medication in relation to risk and prognosis in two cohorts: one composed of young healthy women from high-risk breast cancer families and the other of breast cancer patients from the general population. LÄS MER